c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6272-6281

  Ma, Patrick C ^a,b,c   Kijima, Takashi ^a   Maulik, Gautam ^a   Fox, Edward A ^a   Sattler, Martin ^a   Griffin, James D ^a   Johnson, Bruce E ^a   Salgia, Ravi ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; INTERLEUKIN 3; PAXILLIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; TYROSINE;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; DIGESTIVE SYSTEM CANCER; EXON; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; INTRON; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; METASTASIS; MICROSCOPY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTO ONCOGENE; RAT; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; ANIMALS; CARCINOMA, SMALL CELL; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETAL PROTEINS; CYTOSKELETON; DNA MUTATIONAL ANALYSIS; HUMANS; LUNG NEOPLASMS; MICE; MUTATION, MISSENSE; PAXILLIN; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; RATS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0141988690     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA Cancer J. Clin., 53: 5-26, 2003.
2. Chute, I. P., Chen, T., Feigal. E., Simon, R., and Johnson, B. E. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol., 17: 1794-1801, 1999.
3. Salgia, R., and Skarin, A. T. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16: 1207-1217, 1998.
4. Kijima, T., Maulik, G., Ma, P. C., Tibaldi, E. V., Turner, R. E., Rollins, B., Sattler, M., Johnson, B. E., and Salgia, R. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res., 62: 6304-6311, 2002.
5. Wang, W. L., Healy, M. E., Sattler, M., Verma, S., Lin, J., Maulik, G., Stiles, C. D., Griffin, J. D., Johnson, B. E., and Salgia, R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19: 3521-3528, 2000.
6. Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., and Salgia, R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev., 13: 41-59, 2002.
7. Maulik, G., Kijima, T., Ma, P. C., Ghosh, S. K., Lin, J., Shapiro, G. I., Schaefer, E., Tibaldi, E., Johnson, B. E., and Salgia, R. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res., 8: 620-627, 2002.
8. Jeffers, M., Rong, S., and Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell. Biol., 16: 1115-1125, 1996.
9. Horiguchi, N., Takayama, H., Toyoda, M., Otsuka, T., Fukusato, T., Merlino, G., Takagi, H., and Mori, M. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene, 21: 1791-1799, 2002.
10. Imai, J., Watanabe, M., Sasaki, M., Yamaguchi, R., Tateyama, S., and Sugano, S., Induction of c-met proto-oncogene expression at the melastatic site. Clin. Exp. Metastasis, 17: 457-462, 1999.
11. Di Renzo, M. F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., Giordano, S., et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res., 1: 147-154, 1995.
12. Horikawa, T., Sheen, T. S., Takeshita, H., Sato, H., Furukawa, M., and Yoshizaki, T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am. J. Pathol., 159: 27-33, 2001.
13. Trusolino, L., and Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer, 2: 289-300, 2002.
14. Petrelli, A., Gilestro, G. F., Lanzardo, S., Comoglio, P. M., Migone, N., and Giordano, S. The endophilin-CIN85-Cb1 complex mediates ligand-dependent downregulation of c-Met. Nature (Lond.), 416: 187-190, 2002.
15. Ma, P. C., Maulik, G., Christensen, J. G., and Salgia, R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastatic Rev., 22: 309-325, 2003.
16. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn Glenii, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bemucs, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., Zbar, B., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
17. Schmidt, L., Junker, K., Weirich, G., Glenn, G., Choyke, P., Lubensky, I., Zhuang, Z., Jeffers, M., Vande Woude, G., Neumann, H., Walther, M., Linehan, W. M., and Zbar, B. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res., 58: 1719-1722, 1998.
18. Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., Vocke, C., Brown, J. A., Jenkins, R., Richard, S., Bergerheim, U., Gerrard, B., Dean, M., Linchan, W. M., and Zbar, B. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 18: 2343-2350, 1999.
19. Salgia, R., Li, J. L., Ewaniuk, D. S., Pear, W., Pisick, E., Burky, S. A., Ernst, T., Sattler, M., Chen, L. B., and Griffin, J. D. BCR/ABL induces multiple abnormalities of cytoskeletal function. J. Clin. Investig., 100: 46-57, 1997.
20. Angeloni, D., Danilkovitch-Miagkova, A., Ivanov, S. V., Breathnach, R., Johnson, B. E., Leonard, E. J., and Lennan, M. I. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer, 29: 147-156, 2000.
21. Yu, J., Miehlke, S., Ebert, M. P., Hoffmann, J., Breidert, M., Alpen, B., Starzynska, T., Stolte Prof, M., Malfertheiner, P., and Bayerdorffer, E. Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer (Phila.), 88: 1801-1806, 2000.
22. Heideman, D. A., Snijders, P. J., Bloemena, E., Meijer, C. J., Offerhaus, G. J., Meuwissen, S. G., Gerritsen, W. R., and Craanen, M. E. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J. Pathol., 194: 428-435, 2001.
23. Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., and Vande Woude, G. F. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol., 12: 5152-5158, 1992.
24. Rong, S., Oskarsson, M., Faletto, D., Tsarfaty, I., Resau, J. H., Nakamura, T., Rosen, E., Hopkins, R. F., III, and Vande Woude, G. F. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ., 4: 563-569, 1993.
25. Oskam, R., Coulier, F., Ernst, M., Martin-Zanca, D., and Barbacid, M. Frequent generation of oncogenes by in vitro recombination of TRK protooncogene sequences. Proc. Natl. Acad. Sci. USA, 85: 2964-2968, 1988.
26. Salgia, R., Avraham, S., Pisick, E., Li, J. L., Raja, S., Greenfield, E. A., Sattler, M., Avraham, H., and Griffin, J. D. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J. Biol. Chem., 271: 31222-31226, 1996.
27. Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., and Vande Woude, G. F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA, 94: 11445-11450, 1997.
28. Lee, J. H., Han, S. U., Cho, H., Jennings, B., Gerard, B., Dean, M., Schmidt, L., Zbar, B., and Vande Woude, G. F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene, 19: 4947-4953, 2000.
29. Meng, Q., Mason, J. M., Porti, D., Goldberg, I. D., Rosen, E. M., and Fan, S. Hepatocyte growth factor decreases sensitivity to chemotherapeutic agents and stimulates cell adhesion, invasion, and migration. Biochem. Biophys. Res. Commun., 274: 772-779, 2000.
30. Phelps, R. M., Johnson, B. E., Ihde, D. C., Gazdar, A. F., Carbone, D. P., McClintock, P. R., Linnoila, R. I., Matthews, M. J., Bunn, P. A., Jr., Camey, D., Minna, J. D., and Mulshine, J. L. NC1-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. Suppl., 24: 32-91, 1996.
31. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., and Misawa, S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (Baltimore). 10: 1911-1918, 1996.
32. Carncy, D. N., Gazdar, A. F., Bepler, G., Guccion, J. G., Marangos, P. J., Moody, T. W., Zweig, M. H., and Minna, J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant feitures. Cancer Res., 45: 2913-2923, 1985.
33. Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., and Vande Woude, G. F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (Lond.), 311: 29-33, 1984.
34. Soman, N. R., Correa, P., Ruiz, B. A., and Wogan, G. N. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl. Acad. Sci. USA, 88: 4892-4896, 1991.
35. 2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell, 106: 745-757, 2001.
36. Baxter, R. M., Secrist, J. P., Vaillancourt, R. R., and Kazlauskas, A. Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. J. Biol. Chem., 273: 17050-17055, 1998.
37. Irusta, P. M., and DiMaio, D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J., 17: 6912-6923, 1998.
38. Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., and Naoe, T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19: 624-631, 2000.
39. Regnauld, K., Nguyen, Q. D., Vakaet, L., BruyneeI, E., Launay, J. M., Endo, T., Mareel, M., Gespach, C., and Emami, S. G-protein α (olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene, 21: 4020-4031, 2002.
40. Zelivianski, S., Verni, M., Moore, C., Kondrikov, D., Taylor, R., and Lin, M. F. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim. Biophys. Acta, 1539: 28-43, 2001.
41. Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani, A. D., Valente, G., Giordano, S., Cortesina, G., and Comoglio, P. M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19: 1547-1555, 2000.
42. Sattler M., Pisick, E., Morrison, P. T., and Salgia, R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit. Rev. Oncog., 11: 63-76, 2000.
43. Sattler, M., and Salgia, R. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia (Baltimore), 12: 637-644, 1998.
44. Liu, Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene (Amst.), 215: 159-169, 1998.
45. Wang, Z., Lo, H. S., Yang, H., Gere, S., Hu, Y., Buetow, K. H., and Lee, M. P. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res., 63: 655-657, 2003.
46. Modrek, B., and Lee, C. A genomic view of alternative splicing. Nat. Genet., 30: 13-19, 2002.
47. Lee, C. C., and Yamada, K. M. Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site. J. Biol. Chem., 269: 19457-19461, 1994.
48. Lee, C. C., and Yamada, K. M. Alternatively spliced juxtmembrane domain of a tyrosine kinase receptor is a multifunctional regulatory site. Deletion alters cellular tyrosine phosphorylation pattern and facilitates binding of phosphatidylinositol-3-OH kinase to the hepatocyte growth factor receptor. J Biol Chem, 270: 507-510, 1995.
49. Goshima, Y., Ito, T., Sasaki, Y., and Nakamura, F. Semaphorins as signals for cell repulsion and invasion. J. Clin. Investig. 109: 993-998, 2002.
50. Kagoshima, M., and Ito, T. Diverse gene expression and function of semaphorins in developing lung: positive and negative regulatory roles of semaphorins in lung branching morphogenesis. Genes Cells, 6: 559-571, 2001.
51. Roche, J., Boldog, F., Robinson, M., Robinson, L., Varella-Garcia, M., Swanton, M., Waggoner, B., Fishel, R., Franklin, W., Gemmill, R., and Drabkin, H. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene, 12: 1289-1297, 1996.
52. Morotti, A., Mila, S., Accomero, P., Tagliabue, E., and Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene, 21: 4885-4893, 2002.
53. Sattler, M., Pride, Y. B., Ma, P. C., Gramlich, J. L., Chu, S. C., Quinnan, L. A., Shirazian, S., Liang, C., Podar, K., Christensen, J. a., and Salgia, R. A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res., 63: 5462-5469, 2003.